Back to Search
Start Over
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
- Source :
- iScience, Vol 24, Iss 2, Pp 102054-(2021), iScience
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Summary The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response.<br />Graphical Abstract<br />Highlights • Vaccine candidates, BBV152 induced potent humoral immune response in Syrian hamsters • Early viral clearance from lower respiratory tract in vaccinated hamsters • BBV152 vaccine candidates protected Syrian hamsters from pneumonia<br />Biological Sciences; Immunity; Immunology; Viral Microbiology; Virology
- Subjects :
- 0301 basic medicine
viruses
Immunology
Hamster
02 engineering and technology
Article
Virus
03 medical and health sciences
Immune system
Immunity
Virology
Viral Microbiology
Medicine
lcsh:Science
skin and connective tissue diseases
Multidisciplinary
biology
business.industry
Immunogenicity
Biological Sciences
021001 nanoscience & nanotechnology
respiratory tract diseases
Vaccination
030104 developmental biology
medicine.anatomical_structure
biology.protein
lcsh:Q
Antibody
0210 nano-technology
business
Respiratory tract
Subjects
Details
- ISSN :
- 25890042
- Volume :
- 24
- Database :
- OpenAIRE
- Journal :
- iScience
- Accession number :
- edsair.doi.dedup.....b7227e70f3a2117fc3efb29a9f4e760f